依达拉奉右莰醇神经保护作用机制及临床应用进展  

Neuroprotective mechanism and clinical application progress of edaravone dexborneol

作　　者：梁新 王亚丽 LIANG Xin;WANG Yali(Department of Encephalopathy,Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712046,China)

机构地区：[1]陕西中医药大学附属医院脑病科,陕西咸阳712046

出　　处：《陕西医学杂志》2022年第2期249-252,F0003,共5页Shaanxi Medical Journal

基　　金：国家自然科学基金资助项目(30973829)。

摘　　要：脑卒中是我国成年人致死和致残的首位原因,及时开展溶栓是急性缺血性脑卒中(AIS)的首选方案,但遗憾的是,我国AIS患者溶栓治疗现状不佳。依达拉奉右莰醇是一种新型多靶点神经保护剂,其良好的脑保护作用已得到国内临床研究的证实,为我国AIS患者的治疗带来了新选择。其具有独特的清除自由基、保护神经血管单位和抑制炎症因子、蛋白表达的作用,经Ⅲ期临床研究证实,对比单方依达拉奉注射液,依达拉奉右莰醇疗效优势明显,临床安全性相似,具备更高的临床应用价值。现对依达拉奉右莰醇作用机制及临床应用进展进行综述。Stroke is the leading cause of death and disability for adults in China.Thrombolytic therapy is the first choice for acute ischemic stroke(AIS).But unfortunately,the current situation of thrombolytic therapy for patients with AIS in China is not good.Edaravone dexborneol is a new type of multi-target neuroprotective agent,and its good brain protection has been confirmed by domestic clinical studies,which brings a new choice for the treatment of AIS patients in China.It has unique functions of scavenging free radicals,protecting neurovascular units,and inhibiting the expression of inflammatory factors and proteins.PhaseⅢclinical studies have confirmed that compared with unilateral edaravone injection,edaravone dexborneol has obvious therapeutic advantages,similar clinical safety and higher clinical application value.In this paper,the neuroprotective mechanism and clinical application progress of edaravone dexborneol are reviewed.

关 键 词：依达拉奉右莰醇 神经保护剂 缺血性脑卒中 氧自由基 神经血管单位 炎症因子 

分 类 号：R743.3[医药卫生—神经病学与精神病学]